Bausch & Lomb Corp
BLCO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$65.00 | Xmtqhp | Qcljmff |
Bausch & Lomb Sees Future in Dry Eye Disease Market With Miebo and Xiidra
Business Strategy and Outlook
Bausch & Lomb is one of the largest vision care companies in the U.S. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals.